Real-time global intelligence

© 2026 OpenWatch. All rights reserved.

For informational and entertainment purposes only. Not investment advice.

Platform

Brief
Signals
Countries
Companies
Industries
Themes
Scenarios
Rankings

Tools

Globe
Analytics
Crises
Clusters
Supply Chain
Alliances
Screener
Watchlist
Portfolio

Developer

API Reference
Developer Keys
Webhooks
Status

Sources

View all sources →

1,000+ tracked sources

Signals updated every 15 minutes

Not investment advice. OpenWatch is provided for informational and entertainment purposes only. While we strive for accuracy, precision, and source attribution in all intelligence assessments, geopolitical analysis involves inherent uncertainty and our conclusions may be incomplete, delayed, or incorrect. Nothing on this platform constitutes financial, investment, legal, or professional advice of any kind. Forward-looking scenarios and probability estimates are analytical hypotheses — not independently validated forecasts. Any actions taken based on information found here are solely your responsibility. Always consult a qualified financial advisor before making investment decisions. Past signal patterns do not guarantee future outcomes.

Methodology
Privacy Policy
Terms of Use

openwatch.io

v·ce3d7be

Company Intelligence

Due diligence intelligence for active companies. Signal-scored across geopolitical exposure, regulatory risk, and sector tailwinds — ranked by composite risk/opportunity score.

Filters:🇩🇪 Germany ✕

All energy technology financials healthcare industrials consumer materials utilities defense semiconductors mining pharma telecom shipping agriculture real_estate

All postures ✦ Opportunities ⚠ Risks

Themes for pharma

💊Pharma Supply Chain Reshoring

1

Total Tracked

0

Opportunities

1

Risk Flags

No data

✦

Opportunities

(0)

Ticker

Company

Sector

Action

Flag

Score

No opportunities in this filter

⚠

Risks

(1)

Ticker

Company

Sector

Action

Flag

Score

BAYRY

🇩🇪Bayer AG

Bayer remains structurally impaired by Roundup litigation th

Bayer remains structurally impaired by Roundup litigation that the new CEO's plan has not resolved.

Bayer remains structurally impaired by Roundup litigation that the new CEO's plan has not resolved. Xarelto LOE is hitting hard with no Phar

AVOID

-22—